Hepatocellular Carcinoma
HCC trial misses OS endpoint, but researchers report ‘clinically meaningful’ benefit with nivolumab
Cabometyx superior to Stivarga as second-line liver cancer treatment
Treatment with Cabometyx as second-line therapy for patients with advanced hepatocellular carcinoma who previously received Nexavar demonstrated superior progression-free survival and improved overall survival compared with Stivarga, according to a study presented at the International Liver Cancer Association 2019 meeting and a press release.
Novel radiotherapy for liver cancer demonstrates complete, partial responses
Milciclib for Nexavar-resistant liver cancer meets additional study endpoints
Elevated fatty liver index in HCV/HIV coinfection predicts mortality risk
FDA grants breakthrough designation to liver cancer liquid biopsy test
Liver transplant update: 6 reports on living vs. deceased donor outcomes
Recent studies have shown significant differences in patient survival and complications after liver transplantation with either a living donor or deceased donor organ. Additionally, awareness about living donor transplantation and the safety records for donors remains low among both physicians and the public.
Public insurance a risk factor for worse liver transplant waitlist outcomes
Liver cancer outcomes improving as physicians gain experience with Nexavar
Top stories in hematology/oncology: Allergan recalls breast implants linked to lymphoma, FDA grants breakthrough therapy designation to hepatocellular carcinoma drug
The top stories in hematology/oncology last week both resulted from FDA actions: Allergan’s agreeing to the agency’s request to recall specific models of its breast implants that may be related to a rare type of lymphoma and the agency granting breakthrough therapy designation to the Keytruda-Lenvima combination for hepatocellular carcinoma.